In the search for novel, clinical, useful molecular-targeted imaging biomarkers that may improve staging and grading and thus also hopefully improve outcome in RCC patients, a number of authors have reported on 68Ga-PSMA-PET CT imaging results in RCC patients. This evidence concerns the gene FOLH1 and renal cell carcinoma.